Abstract
Purpose
Development of improved protocols for differentiating induced pluripotent stem (iPS) cells into hepatic cells is an important step toward their use in the field of hepatology. Specifically, the number of different cytokines should be reduced to limit undesired effects and to reduce the cost of the process. In this report, we describe a simple method for directing human iPS cells to differentiate into hepatic cells using only two cytokines and a short incubation time.
Methods
A two-step protocol for differentiating iPS cells into hepatic cells was developed. A high dose of activin A was applied for 3 days to induce definitive endoderm formation. Subsequently, cells were treated with hepatocyte growth factor (HGF) for 5 days to generate hepatic cells. Differentiation was confirmed by immunostaining for differentiation markers. Albumin mRNA levels in differentiated hepatic cells generated using a previously tested three-step protocol that uses activin A, fibroblast growth factor (FGF)/bone morphogenetic protein (BMP), and HGF, and our new protocol were compared to determine the efficiency of differentiation.
Results
Our two-step protocol induced the differentiation of iPS cells into hepatic cells and required a shorter differentiation period than the previous three-step protocol. The differentiation efficiencies of the two protocols were comparable and the induced hepatic cells were functional.
Conclusions
Developing efficient induction and culture methods to generate more highly matured hepatocytes is essential for regenerative cell-based therapies. Our protocol provides a simple, cost-effective, and time-saving approach for generating hepatic cells from iPS cells.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Induced pluripotent stem (iPS) cells have been generated from mature somatic fibroblasts through over-expression of four transcription factors: Oct-4, Sox2, Klf4, and c-Myc [1]. Since the initial creation of iPS cells, much effort has gone into improving the methods used to generate them, including the use of chemical induction and avoiding or reducing the use of inducing genes [2–5]. Human iPS cells have been shown to resemble human embryonic stem (hES) cells in terms of pluripotency [6]. Indeed, iPS cells are apparently able to proliferate infinitely and differentiate into cell types of various lineages in vitro [7, 8]. Differentiated cells generated from iPS cells derived from patients have great potential in regenerative medicine in tissue replacement and cell-based therapies, and may also help with drug discovery and/or in understanding disease pathogenesis.
To date, human iPS cells have been shown to differentiate into various cell types including cardiovascular cells [9], pancreatic cells [10, 11], neural cells [12], and hematopoietic cells [13, 14]. Several studies have also demonstrated the capacity of human iPS cells to differentiate into hepatocyte-like cells [15–17]. Notably, two recent studies reported the first successful differentiation of human iPS cells into endoderm-derived hepatocytes [15, 17]. However, while the protocols used to generate specific cell types from iPS cells have been continually improved, those presently being used still involve the use of multiple undefined and expensive growth factors and/or cytokines and are time-consuming. Thus, the development of simpler approaches for differentiating iPS cells into hepatocytes will be a great advantage for their potential future use.
In protocols used in recent studies to induce the formation of hepatic cells from human iPS cells, activin A has been used to induce endodermal cell formation, and BMP4 and FGF2 then specify hepatic cell formation, and, subsequently, HGF specifies hepatic cell formation [15]. However, because the rationale for using these cytokines is based largely on studies of mouse embryonic development, it remains to be determined whether the use of these cytokines, and the culture conditions are, in fact, optimal for the induction of hepatic cell formation from human iPS cells in vitro. In this study, we report a simpler, cost-effective, and time-saving protocol for driving human iPS cells to differentiate into hepatic cells using only two cytokines.
Methods
Cytokines
Basic fibroblast growth factor (bFGF) was obtained from Invitrogen (Carlsbad, CA). Activin A was acquired from Sigma-Aldrich (St. Louis, MO). HGF, fibroblast growth factor 4 (FGF4), and bone morphogenetic protein 2 (BMP2) were purchased from Wako (Osaka, Japan). Oncostatin M was purchased from R&D Systems (Minneapolis, MN).
Antibodies
A rabbit anti-HNF3β/FOXA2 antibody (#07-633; Millipore, Temecula, CA), a goat anti-SOX17 antibody (MAB1924; R&D systems), a rabbit anti-α-fetoprotein (AFP) antibody (N1501; Dako, Kyoto, Japan), and a goat anti-albumin antibody (A80-129A; Bethyl Laboratories Inc., Montgomery, TX) were used.
Cell culture
STO cells (mouse embryonic fibroblast cell lines) were obtained from the European Collection of Cell Cultures (ECACC; Porton Down, UK) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM glutamine and 10% fetal bovine serum. Cells were treated with mitomycin C (20 μg/mL; Nacalai Tesque, Kyoto, Japan) for 3 h and were plated in 0.1% gelatin-coated 60 or 35 mm dishes (1.5 × 105 cells/mL) the following day to be used as feeder cells for iPS cell culture. Two human iPS cell lines, HPS0001, and HPS0002, which were established by transducing human fibroblasts with lentiviruses carrying Oct-3/4 Sox2 and Klf4, with or without c-Myc, respectively [2, 7], were obtained from the Riken Bioresource Centre (Ibaraki, Japan). iPS cells were seeded onto mitomycin C-treated STO cells and were cultured at 37°C in a standard humidified gas atmosphere containing 5% CO2 Primate ES medium (ReproCELL, Kanagawa, Japan) supplemented with bFGF (5 ng/mL) was used to maintain iPS cell growth, according to supplier’s instructions. The growth medium was replaced daily.
Hepatic differentiation of human iPS cells
To drive iPS cells to differentiate directly into endodermal cells without embryoid body formation, iPS cells were seeded at 70–80% confluence and were incubated in serum-free RPMI 1640 medium (Invitrogen) supplemented with B27 (Invitrogen) and activin A (100 ng/mL) for 3 days. Subsequently, differentiated endodermal cells were treated with HGF (20 ng/mL) for 5 days to generate hepatic cells. To achieve final hepatic cell maturation, cells were cultured for 5 days in hepatocyte culture medium (HCM; Lonza, Walkersville, MD) supplemented with oncostatin M (10 ng/mL) according to the manufacturer’s protocol. Other iPS cells were subjected to the three-step protocol [15, 17, 18]. They were cultured in RPMI 1640 medium supplemented with B27 and activin A (100 ng/mL) for 5 days to induce endodermal cell formation. The endodermal cells formed were then treated with BMP2 (30 ng/mL) and FGF4 (20 ng/mL) for 5 days, followed by HGF (20 ng/mL) for an additional 5 days. To induce hepatic maturation, cells were cultured for 5 days in HCM containing oncostatin M (10 ng/mL), as in our new protocol. In both protocols, cells were maintained in HCM with no oncostatin M after hepatic cell maturation. The growth medium was replaced every other day.
Immunocytochemical staining
Cells were fixed in 2% paraformaldehyde for 30 min and then permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 10 min. They were next incubated with primary antibody for 1 h at room temperature. Alexia Fluor 488- and 594-conjugated secondary antibodies (Invitrogen) were applied to the cells for 1 h at room temperature. Cell nuclei were stained with 4′,6-diamino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and the cells were mounted using cover slips.
RNA isolation, reverse transcription, and quantitative real-time (RT)-PCR
Total cellular RNA was isolated using the Trizol Reagent (Invitrogen) and was used as a template for cDNA synthesis, performed using the superscript III first-strand synthesis system (Invitrogen). Quantitative real-time PCR was performed using the TaqMan gene expression system and SYBR Green (Applied Biosystems, Foster City, CA). Target gene expression values were normalized to those for the housekeeping gene GAPDH, and relative expression levels calculated by the ΔΔCT method (ΔΔCT = ΔCTsample − ΔCTgapdh). The following primers were used: albumin, (forward) 5′-GCC TGC TGA CTT GCC TTC ATT AG-3′, (reverse) 5′-TCA GCA GCA GCA CGA CAG AGT A-3′; HNF4α, (forward) 5′-GGA ACA TAT GGG AAC CAA CA-3′, (reverse) 5′-AAC TTC CTG CTT GGT GAT GG-3′; CYP7A1, (forward) 5′-TGT TCA GGA CTG CGC ACA ATG-3′, (reverse) 5′-AGG ATT GCC TTC CAA GCT GAC-3′; CYP3A4, (forward) 5′-CAT TCC TCA TCC CAA TTC TTG AAG T-3′, (reverse) 5′-CCA CTC GGT GCT TTT GTG TAT CT-3′; and GAPDH, (forward) 5′-ATC AAC GAC CCC TTC ATT GAC C-3′, (reverse) 5′-CCA GTA GAC TCC ACG ACA TAC TCA GC-3′.
Urea assay
Cell culture supernatant urea concentrations were screened using a colorimetric assay (Bio Vision, Mountain View, CA), according to the manufacturer’s instructions. Absorbances were measured at 570 nm using a microplate reader (model 680; Bio-Rad, Hercules, CA).
Enzyme-linked immunosorbent assay (ELISA) for albumin secretion
Levels of human albumin in cell culture supernatants were determined using a human albumin ELISA quantitation set (Bethyl Laboratory, Montgomery, TX) according to the manufacturer’s instructions.
Cytochrome P450 (CYP) activity assay
CYP3A4 activity was assessed using a non-lytic method involving the P450-GLO screening system (Promega, Madison, WI) according to manufacturer’s instructions. Cells were incubated with luminogenic substrate at 37°C for 1 h. CYP activity was then determined using a luminometer (Lumat LB9507; EG&G Berthold, Bad Wildbad, Germany) as relative light units per mL of tissue culture medium (RLU/mL).
Periodic acid Schiff (PAS) staining for glycogen
To detect glycogen, differentiated cells were stained using a PAS staining kit (Muto Pure Chemicals, Tokyo, Japan). Briefly, cells were fixed in 4% paraformaldehyde for 10 min, and were then oxidized through incubation with 1% periodic acid solution for 10 min. They were then incubated with freshly prepared Schiff’s reagent at 37°C for 30 min. After the cells were rinsed with sulfurous acid, nuclei were counterstained through incubation with Mayer’s hematoxylin for 5 min.
Results
New two-step protocol to drive iPS cells to differentiate into hepatic cells
A protocol for inducing iPS cells to differentiate into hepatic cells was recently described [15, 17]. It comprises three steps: (1) the treatment of iPS cells with 100 ng/mL activin A for 5 days to induce their differentiation into endodermal cells; (2) the treatment of iPS-derived endodermal cells with 30 ng/mL FGF4 and 20 ng/mL BMP2 for 5 days; and (3) incubation of the cells with 20 ng/mL HGF for 5 days to generate hepatic cells (Fig. 1a). When hepatic maturation was required, the cells were cultured in HCM supplemented with 10 ng/mL oncostatin M for a further 5 days (Fig. 1a). Although this protocol is relatively simple, it uses several cytokines, which are expensive and may produce unwanted effects, and is time-consuming—at least 2 weeks are required to generate hepatic cells.
To develop a method to generate hepatic cells from iPS cells using fewer cytokines, we referred to several protocols describing the generation of hepatocytes from embryonic stem (ES) cells [18–22]. Of the factors tested, the combination of activin A and HGF was found to be most effective in inducing the differentiation of human ES cells into hepatic cells [21]. Thus, we adapted this previous method to the generation of hepatic cells from human iPS cells. Following treatment with 100 ng/mL activin A for 3 days, cells were cultured with 20 ng/mL HGF for 5 days to generate hepatic cells. Thus, our protocol for generating hepatic cells from human iPS cells uses only two factors: high-dose activin A and HGF (Fig. 1b, c).
Efficient differentiation of iPS cells into ectoderm cells in the new two-step protocol
In our study, we used a high dose of activin A (100 ng/mL), known to efficiently induce definitive endoderm formation [23, 24]. In fact, after treatment with activin A for 3 days, the iPS cells began to express FOXA2—a well-established endodermal marker—that displayed nuclear, but not nucleolar, immunolocalization (Fig. 2a). In addition, Sox17, another established endoderm marker, was detected (Fig. 2a), confirming that the cells were endodermal. The staining of these endodermal markers was detected in 50–75% of cells formed from two different parental iPS cell lines (Fig. 2b), suggesting that the observed phenomena were not cell type-specific. These results indicate that a high dose of activin A was sufficient to induce the differentiation of iPS cells into endodermal cells, consistent with reports of similar outcomes using ES cells [23, 24].
Levels of AFP and albumin expression in the hepatic cells generated using the new protocol were comparable to those in cells produced using the three-step protocol
After treatment with HGF for 5 days, we evaluated the cells’ differentiation status by immunostaining for the hepatic cell markers AFP and albumin. As shown in Fig. 3, both AFP and albumin were expressed in the cytoplasm in about 40% of cells (Fig. 3a, b). Numbers of AFP- and albumin-expressing cells were comparable when our new two-step protocol and the original three-step protocol were employed (Fig. 3b), and were similar to those reported previously [15]. These results suggest that the endodermal cells generated using our two-step protocol differentiated into hepatic cells with similar efficiency to those generated using the original three-step protocol.
Hepatic function of the induced hepatic cells generated using the new protocol was comparable to that of cells produced using the three-step protocol
Although cells treated with activin A and HGF expressed hepatic markers, such as AFP and albumin, levels of albumin secreted into the culture medium were too low to be detected by ELISA (data not shown). To induce additional hepatic maturation, cells were cultured in HCM supplemented with 10 ng/mL oncostatin M for further 5 days [25, 26]. To compare the hepatic cells’ differentiation status, urea production (Fig. 4a, left panel), albumin secretion (Fig. 4a, right panel), CYP3A4 activity (Fig. 4b), and glycogen deposition (Fig. 4c) were examined in the cells generated from two different parental iPS cells using the three-step protocol and our new two-step protocol. Cells generated using the two protocols were found to display comparable hepatic function (Fig. 4a, c). In fact, our new protocol may be slightly superior in terms of hepatic function of the cells generated. Consistent with these findings, mRNA expression of a panel of hepatic markers, consisting of albumin, HNF4α, CYP3A4, and CYP7A1, was also comparable between cells generated using the three-step protocol and our new protocols (Fig. 4d). In particular, CYP7A1 expression is used to indicate that those cells are derived from definitive endoderm cells [27]. These results suggest that our protocol, using only two factors (activin A and HGF) is as efficient at generating hepatic cells from iPS cells as the three-step protocol using four factors (activin A, FGF4, BMP, and HGF). In addition, omitting the FGF4 and BMP2 treatment step shortens the protocol’s duration.
Discussion
We report here that human iPS cells can be induced to differentiate into hepatic cells through sequential treatment with only two factors, activin A and HGF. This method is as efficient as previously described protocols. In addition, it requires a shorter culture period.
Our protocol used a high dose of activin A to induce the formation of definitive endoderm from iPS cells, similar to a previous protocol using ES cells [23, 24]. Nodal, a member of the TGF-β super family, directs the formation of definitive endoderm [28]. Previous studies reported that activin A binds to the same receptor as Nodal and that high doses of activin A effectively induce the formation of definitive endoderm from human ES cells [23, 24]. These results were the rationale for our use of a high dose of activin A to generate endodermal cells from iPS cells. In fact, we were similarly able to induce iPS cells to differentiate into endodermal cells using only a high dose of activin A.
The second cytokine used in this study, HGF, which is critical for the development and regeneration of the liver, appears to be essential for driving endodermal cells to differentiate into hepatic cells [29–31]. We used HGF to differentiate our induced endodermal cells into hepatic cells. The hepatic cells generated using our protocol exhibited differentiation comparable to those produced using the three-step protocol, as assessed by expression of the hepatic cell markers AFP and albumin. This suggests that HGF is sufficient to induce the differentiation of endodermal cells into hepatic cells. A recent study showed that hepatocyte-like cells could be generated from iPS cells using FGF4 and BMP2 to induce endodermal cells to differentiate along the hepatic lineage [15]. We found these cytokines to be non-essential. Instead, our results are consistent with those of another recent study that focussed on the generation of hepatic cells from human ES cells [21]. In that study, activin A plus HGF was found to be the most effective combination for inducing the differentiation of human ES cells into AFP-positive and albumin-positive hepatic cells (combinations of other cytokines including activin A, FGF, BMP, and HGF were also tested). Moreover, FGF/BMP reduced the effects of activin A and HGF on hepatic differentiation [21]. In vertebrate embryos, hepatogenesis from the endoderm layer has been reported to begin on embryonic day 8, triggered by FGFs produced by the cardiac mesoderm [32]. However, a previous study demonstrated that FGFs have much smaller effects on the transition from albumin-negative stem cells to albumin-positive cells in fetal hepatic cell differentiation [25]. Although FGFs may directly induce the differentiation of hepatic cells from foregut endoderm, HGF also stimulates the differentiation of dormant stem cells. Moreover, HGF has strong stimulatory effects on the differentiation of hepatic cells from hematopoietic stem cells [33] and hES cells [34]. Thus, HGF may play important roles in hepatic cell differentiation and proliferation. In addition, the results of previous studies suggested that HGF directly regulates the expression of C/EBPα, which regulates liver-specific gene expression and cell proliferation and also promotes the differentiation of stem cells into hepatic cells [35]. In fact, previous studies demonstrated efficient maturation of hepatic cells generated from human ES cells using only HGF [21], and of hepatic cells generated from mouse fetal hepatic cells using a combination of HGF with oncostatin M [25]. These observations may support our use of activin A and HGF, without FGF4 or BMP2, to efficiently generate hepatic cells from iPS cells.
Although the methods used to generate hepatic cells from iPS cells are continually being improved, further studies are needed to optimize the induction and culture protocols used to produce, from induced hepatic cells, mature hepatocytes that may be used in regenerative cell-based therapies. Nonetheless, the protocol we have described here provides a simple, cost-effective, and time-saving approach for generating hepatic cells from iPS cells. We hope that it will facilitate the future use of iPS cells in the field of hepatology.
References
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101–106
Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;2:525–528
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269–1275
Li W, Zhou H, Abujarour R, Zhu S, Young JooJ, Lin T, Hao E, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009;27:2992–3000
Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313–317
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917–1920
Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008;118:498–506
Tateishi K, He J, Taranova O, Liang G, D’Alessio AC, Zhang Y. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008;283:31601–31607
Zhang D, Jiang W, Liu M, Sui X, Yin X, Chen S, Shi Y, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res 2009;19:429–438
Karumbayaram S, Novitch BG, Patterson M, Umbach JA, Richter L, Lindgren A, Conway AE, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009;27:806–811
Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M, Thomson J, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009;27:559–567
Lengerke C, Grauer M, Niebuhr NI, Riedt T, Kanz L, Park IH, Daley GQ. Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci 2009;1176:219–227
Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009;19:1233–1242
Sullivan GJ, Hay DC, Park IH, Fletcher J, Hannoun Z, Payne CM, Dalgetty D, et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010;51:329–335
Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010;51:297–305
Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, Meng S, et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007;45:1229–1239
Soto-Gutierrez A, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, Fox IJ, et al. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. Nat Protoc 2007;2:347–356
Hay DC, Fletcher J, Payne C, Terrace JD, Gallagher RC, Snoeys J, Black JR, et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci USA 2008;105:12301–12306
Ishii T, Fukumitsu K, Yasuchika K, Adachi K, Kawase E, Suemori H, Nakatsuji N, et al. Effects of extracellular matrixes and growth factors on the hepatic differentiation of human embryonic stem cells. Am J Physiol Gastrointest Liver Physiol 2008;295:G313–G321
Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010;51:1754–1765
Kubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, Fehling HJ, et al. Development of definitive endoderm from embryonic stem cells in culture. Development 2004;131:1651–1662
D’Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol 2005;23:1534–1541
Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, Nakashima K, et al. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J 1999;18:2127–2136
Miyajima A, Kinoshita T, Tanaka M, Kamiya A, Mukouyama Y, Hara T. Role of Oncostatin M in hematopoiesis and liver development. Cytokine Growth Factor Rev 2000;11:177–183
Asahina K, Fujimori H, Shimizu-Saito K, Kumashiro Y, Okamura K, Tanaka Y, et al. Expression of the liver-specific gene Cyp7a1 reveals hepatic differentiation in embryoid bodies derived from mouse embryonic stem cells. Genes Cells 2004;9:1297–1308
Lowe LA, Yamada S, Kuehn MR. Genetic dissection of nodal function in patterning the mouse embryo. Development 2001;128:1831–43
Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699–702
Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995;345:293–295
Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60–66
Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008;322:1490–1494
Oh SH, Miyazaki M, Kouchi H, Inoue Y, Sakaguchi M, Tsuji T, Shima N, et al. Hepatocyte growth factor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage in vitro. Biochem Biophys Res Commun 2000;279:500–504
Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2000;97:11307–11312
Suzuki A, Iwama A, Miyashita H, Nakauchi H, Taniguchi H. Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. Development 2003;130:2513–2524
Acknowledgements
We thank M. Tsubouchi for excellent technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (#21890052, #17016016, and #20390204) (to M. Otsuka, M. Omata, and K.Koike).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takata, A., Otsuka, M., Kogiso, T. et al. Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. Hepatol Int 5, 890–898 (2011). https://doi.org/10.1007/s12072-011-9251-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-011-9251-5